Mod GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Lactose, maltose and sucrose are disaccharides, also called "compound sugars". They share the formula C12H22O11. They are formed by the condensation of two monosaccharide molecules with the expulsion of a molecule of water.
=== Safety === Mild to moderate gastrointestinal side effects (such as nausea, cramping, bloating, and abdominal discomfort) are common after ESG (reported in over 70% of patients), but these are predictable, temporary, and can be managed with medications. Most will resolve within one week after ESG. Due to the minimally invasive nature of ESG, serious complications are rare. These include pain or nausea requiring hospitalization (1.08%); upper gastrointestinal tract bleeding (0.56%); peri-gastric leak or infected fluid collection (0.48%); pulmonary embolism (0.06%); perforation (0.06%). Similar rates of serious adverse events were reported in the multicenter, randomized controlled MERIT study. No deaths have been observed in the published ESG literature.
In 1910, when Loeb moved to The Rockefeller Institute for Medical Research in New York, Robertson was promoted to Associate Professor of Physiological Chemistry within the School of Medicine; and, in 1916, he was appointed as full Professor of Biochemistry in the new, separate, Department of Biochemistry and Pharmacology that had just been established in the university's School of Medicine. By this time, through his "investigat[ions of the] diverse aspects of mechanisms of growth and longevity in plants, animals and humans", Robertson had already "gained international repute as a leader in the field of biochemistry".
=== In adults === While there are some similarities between adults and children, OSA does not have the same consequences in both populations. Examples of similarities are the snoring – which is the most common complaint in both pediatric OSA and OSA in adults – variability of blood pressure and cardiovascular morbidities. A major difference is the excessive daytime sleepiness (EDS) which is commonly reported in adult OSA, while it is not very common in pediatric OSA. Nevertheless, OSA in adults also implies a large scope of adverse and serious consequences, the latter leading to higher mortality amongst OSA patients. Those consequences are even worsened by common morbidities such as obesity.
=== Blood supply === The rectus abdominis has many sources of arterial blood supply. Classification of the vascular anatomy of muscles: First, the inferior epigastric artery and vein (or veins) run superiorly on the posterior surface of the rectus abdominis, enter the rectus fascia at the arcuate line, and serve the lower part of the muscle. Second, the superior epigastric artery, a terminal branch of the internal thoracic artery, supplies blood to the upper portion. Finally, numerous small segmental contributions come from the lower six intercostal arteries as well.
Sources: en.wikipedia.org
=== Etymology === Obesity is from the Latin obesitas, which means "stout, fat, or plump". Ēsus is the past participle of edere (to eat), with ob (over) added to it. The Oxford English Dictionary documents its first usage in 1611 by Randle Cotgrave.
=== Calvin cycle === The Calvin cycle accounts for 90% of biological carbon fixation. Consuming adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide phosphate (NADPH), the Calvin cycle in plants accounts for the predominance of carbon fixation on land. In algae and cyanobacteria, it accounts for the dominance of carbon fixation in the oceans. The Calvin cycle converts carbon dioxide into sugar, as triose phosphate (TP), which is glyceraldehyde 3-phosphate (GAP) together with dihydroxyacetone phosphate (DHAP):
==== Sarcomas ==== Connective tissue malignancies, sarcomas, are rare in the oral mucosa. Osteosarcoma, chondrosarcoma arise in bone and cartilage, lymphoma in haematological disorders. The most common malignancies are carcinomas, overwhelmingly squamous cell carcinoma.
In simplifications where the change in reaction quotient is solely due to the concentration changes, Qr is referred to as the mass-action ratio, and the ratio Qr/Keq is referred to as the disequilibrium ratio.
Sources: en.wikipedia.org
=== Chemical handles === Chemical handles are used to detect post-translationally modified proteins. Recently, there is a N6pATP that contains an alkynyl tag (propargyl) at the N6 position of the adenine of ATP. This N6pATP combines with the click reaction to detect AMPylated proteins. To detect unrecognized modified protein and label VopS substrates, ATP derivatives with a fluorophore at the adenine N6 NH2 is utilized to do that.
Ann Kihengu (2010 Africa Laureate) - Tanzanian energy distribution entrepreneur and founder of Pamoja Life, recognized for expanding solar energy and clean cookstove access in rural East Africa. Lianna Gunawan (2012 Asia-Pacific Laureate) - Indonesian footwear supply-chain executive and founder of Amanda Niaria, noted for introducing ethical manufacturing and community-based artisan sourcing to commercial footwear. Chinwe Ohajuruka (2015 Africa Laureate) - Nigerian green architect and founder of Comprehensive Design Services, specialized in producing affordable, solar-powered, and water-self-sufficient housing models for displaced populations. Temie Giwa-Tubosun (2020 Sub-Saharan Africa Fellow) - Nigerian health logistics pioneer and founder of LifeBank, a medical distribution company using tech and cold-chain infrastructure to deliver blood, oxygen, and vaccines to hospitals across Africa. Basima Abdulrahman (2021 Middle East & North Africa Laureate) - Iraqi structural engineer and founder of Kesk, recognized for establishing Iraq's first green building and sustainable engineering consultancy to build solar-powered infrastructure.
=== Nonsegmental vitiligo === In NSV, there is usually a degree of symmetry in the location of depigmentation. It tends to affect more skin over time and can occur in patches or over large portions of the body. NSV can occur at any age (while segmental vitiligo usually first appears in teenagers). Classes of nonsegmental vitiligo include the following:
Marcus S. Albernaz, MD Shirley A. Carraway, Ed.D. James W. "Jim" Chestnutt Charlester T. Crumpler, Jr. Ernest L. "Ernie" Evans Jimmy F. Garris Robert J. "Bob" Greczyn, Jr. W. Phillip "Phil" Hodges J. Bryant Kittrell, III C. Bynum Satterwhite Anand "Andy" Tewari, MD
The dependence of osteosarcoma cells on NMNAT1-derived NAD for the PARP1-dependent DNA repair and survival is not restricted to cisplatin-treated cancer cells but has also been reported to occur in actinomycine D-treated tumor cell lines, as well. These data suggest that nuclear NAD synthesis by NMNAT1 may represent a therapeutic target in osteosarcoma and possibly in other tumors, as well.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.